Healthcare fingerprint security company Rx Safes eyes investment community

By Admin
A Healthcare tech company which also develops autonomous fingerprint security products, Rx Safes, has announced its new partnership with healthcare-focu...

A Healthcare tech company which also develops autonomous fingerprint security products, Rx Safes, has announced its new partnership with healthcare-focused strategic communications firm The Ruth Group as its investor relations counsel.

Rx Safes specializes in personal and professional healthcare drug security market, incorporating patented fingerprint technology to provide theft prevention and medical information solutions.

RELATED TOPIC: How Premera Blue's Breach Reveals Weaknesses in Health Care Security

Prescription drug abuse, drug diversion, rising insurance and high pharmaceutical treatment costs have created an opportunity for Rx Safes to expand in the growing market.

Valued at more than $50 billion a year, the Rx Safes’ annual spending on healthcare technology products is over $34.5 billion. In addition, the market is being driven by ongoing government support for successful drug abuse prevention initiatives that come with a financial commitment of $25.4 billion in 2015.

RELATED TOPIC: How to Defend Your Hospital Against IT Security Breaches

Meanwhile, The Ruth Group supplies PR and investment relations services to a disparate group of innovative healthcare businesses.

“It was important for Rx Safes to partner with an investor relations firm that had a long and successful track record within the healthcare industry,” said Rx Safes CEO Lorraine Yarde. “We look forward to working with The Ruth Group to leverage their expertise and relationships in the industry as we take the next steps in introducing the company to the healthcare and investment community.

RELATED TOPIC: Is RateRx the New Yelp for Drugs?

“We expect to secure a qualified investment banker in the very near future as we anticipate integrating our technology and products into frontline solutions to prevent unauthorized access to and diversion of controlled substances.”

Let's connect!   

Click here to read the latest edition of Healthcare Global magazine!

 

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma